WO2005051349A2 - Compositions pharmaceutiques de mirtazapine - Google Patents

Compositions pharmaceutiques de mirtazapine Download PDF

Info

Publication number
WO2005051349A2
WO2005051349A2 PCT/IB2004/003872 IB2004003872W WO2005051349A2 WO 2005051349 A2 WO2005051349 A2 WO 2005051349A2 IB 2004003872 W IB2004003872 W IB 2004003872W WO 2005051349 A2 WO2005051349 A2 WO 2005051349A2
Authority
WO
WIPO (PCT)
Prior art keywords
mirtazapine
dosage form
sifting
cellulose
anhydrous
Prior art date
Application number
PCT/IB2004/003872
Other languages
English (en)
Other versions
WO2005051349A3 (fr
Inventor
Phanindrudu Aluri
Justin Babu
Shaik Srinivasa Rao
Ashish Gogia
Original Assignee
Aurobindo Pharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd. filed Critical Aurobindo Pharma Ltd.
Priority to EP04798978A priority Critical patent/EP1689371A2/fr
Priority to US10/580,391 priority patent/US20070298107A1/en
Publication of WO2005051349A2 publication Critical patent/WO2005051349A2/fr
Publication of WO2005051349A3 publication Critical patent/WO2005051349A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates ' to pharmaceutical compositions of mirtazapine or its pharmaceutically acceptable salts. More particularly, the present invention relates to solid unit dosage forms of anhydrous mirtazapine or its pharmaceutically acceptable salts suitable for oral administration. The present invention also relates to a process for the preparation of pharmaceutical compositions of mirtazapine or its pharmaceutically acceptable salts.
  • Background of the invention Mirtazapine is disclosed and claimed in US Patent No. 4,062,848. Mirtazapine, is approved, under the trademark REMERON and REMERON SOLTAB by the US Food and Drug Administration, for the treatment of depression.
  • Mirtazapine has a tetra cyclic chemical structure unrelated to other classes of antidepressants such as selective serotonin reuptake inhibitors, tricyclics or monoamine oxidase inhibitors. Mirtazapine is conventionally being marketed as mirtazapine hemihydrate. The usual practice to produce conventional tablets with mirtazapine hemihydrate is to micronize the active ingredient to produce 90 % of the particles ⁇ 100 microns and mix it with excipients and compress it to produce tablets.
  • US patents 6,375,982 and 6,589,556 disclose a rapid melt, semi-solid molded composition comprising: at least one binder in an amount from about 0.01% to about 70% by weight; a salivating agent in an amount from about 0.05% to about 15% by weight; a diluent/bulking material in an amount from about 10% to about 90% by weight; and a therapeutically effective amount of a drug.
  • US Patents 4,371,516, 5,501,816 and 5,720,974 disclose processes for the preparation of porous, rapidly disintegrable tablets, which include the steps of adding a small quantity of a solvent to sugars, alcohols or carbohydrates to obtain a tablet mixture and removing the solvent therefrom.
  • these processes have low productivity due to the involvement of complicated process steps and the tablets obtained thereby are easily friable and do not meet the hardness required for withstanding breakage during commercial handling.
  • WO 01/26621 discloses a pharmaceutical formulation of mirtazapine and pharmaceutically acceptable excipients, characterized in that the dosage unit is of the orally disintegrating type, and the formulation comprises means which substantially prevent mirtazapine from being released orally and the means which substantially prevent mirtazapine from being released orally is a polymer layer coating mirtazapine.
  • Cima Labs has produced oral dosage forms including microparticles and effervescents which rapidly disintegrate in the mouth and provide adequate taste-masking (US patent No. 5,178,878).
  • Zydis on the other hand, produces a rapidly dissolvable, freeze-dried, sugar matrix to produce a rapidly dissolving tablet.
  • Mirtazapine is essentially insoluble in water.
  • Particle Size Distribution (PSD) of mirtazapine crystals are used to determine the available surface area for the drug dissolution, thus effecting the solubility.
  • PSD Particle Size Distribution
  • the available surface area for drug dissolution correlates to the rate of dissolution and solubility where a greater surface area enhances the solubility of a drug and enhances the rate of dissolution of a drug.
  • the velocity of dissolution of a drug often effects the drug's bioavailability.
  • the PSD of mirtazapine and, in particular, the mean particle diameter are important parameters to characterize and predict the bioavailability of the drug. It is desirable to have mirtazapine with a particle size in which the mean particle size enhances the reproducibility of the rate of dissolution and the reproducibility of the dissolution. It is desirable to have mirtazapine in which the mean particle size imparts an improved and stable dissolution profile. Freeze drying processes have been used to prepare fast disintegrating dosage forms. Although this technology produces a product which rapidly disintegrates in water or in the oral cavity, a drawback is represented by the poor physical integrity of its physical structure which severely limits further manufacturing operations such as forming blister packs.
  • the main objective of present invention is to provide compositions for anhydrous mirtazapine in such a way that it will comply with the reference product in terms of in vivo parameters like bioequivalence and in vitro parameters like dissolution, disintegration and etc.
  • Another objective of the present invention is to provide simple, cost effective and efficient process for preparing the solid dosage forms of mirtazapine on a commercial scale with adequate hardness and good reproducibility.
  • Yet another objective of the present invention is to provide film-coated tablets of anhydrous mirtazapine.
  • Yet another objective of the present invention is to provide a hard, compressed, orally disintegrable dosage form of anhydrous mirtazapine.
  • unit dosage forms of anhydrous mirtazapine or its pharmaceutically acceptable salts suitable for oral administration In yet another embodiment of the present invention, there is provided film-coated tablets of mirtazapine which comprises anhydrous mirtazapine or its pharmaceutically acceptable salts, low-substituted hydroxypropylcellulose and one or more pharmaceutically acceptable excipients. In yet another embodiment of the present invention, there is provided a hard, compressed, orally disintegrable tablet dosage form of anhydrous mirtazapine comprising mirtazapine or its pharmaceutically acceptable salts, and one or more non-effervescent excipients.
  • a process for the preparation of film-coated tablets of anhydrous mirtazapine In yet another embodiment of the present invention, there is provided a process for the preparation of film-coated tablets of anhydrous mirtazapine. In yet another embodiment of the present invention, there is provided a process for the preparation of hard, compressed, orally disintegrable tablet dosage form of anhydrous mirtazapine.
  • the present invention involves the use of anhydrous mirtazapine having coarser particle size, which avoids the use of air jet milling to reduce the particle size to ⁇ 100 microns and thereby reduces the length of the unit process.
  • the other advantage of using anhydrous mirtazapine is its ease of handling.
  • the orally disintegrating compressed tablets comprises binders, dispersing agents, fillers, flavoring agents, sweetening agents, lubricants or glidants and the like.
  • pharmaceutically acceptable excipients as used in film coated tablet comprise binders, dispersing agents, fillers, lubricants or glidants and the like.
  • the orally disintegrating compressed tablets comprises anhydrous mirtazapine from about
  • dispersing agent used in accordance with the present invention is selected from crosscarmellose sodium, crosspovidone, sodium starch glycolate, sodium carboxymethyl cellulose, hydroxypropyl cellulose, xanthan gum, alginic acid, alginates, carbopols and the like or combination thereof, preferably dispersing agent used is crosspovidone.
  • the diluents used according to the present invention are selected from calcium phosphate-dibasic, cellulose-microcrystalline, cellulose powdered, calcium silicate, ployols such as mannitol, sorbitol, xylitol, maltitol, sucrose and combinations thereof.
  • Suitable binders according to the present invention are selected from methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, starch, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, alginate, plasdone and the like.
  • Suitable lubricants according to the present invention are selected from talc, magnesium stearate, stearic acid or glyceryl behenate, preferably magnesium stearate and suitable glidants include colloidal silicon dioxide or talc, preferably colloidal silicon dioxide.
  • Suitable sweeteners according to the present invention is selected from sugars such as sucrose, lactose and glucose; saccharin and salts thereof; mannitol and aspartame.
  • Suitable flavoring agents include strawberry guarana, peppermint, cherry, mint, caramel, raspberry, lemon, orange, tuttifruity, banana, bubble gum, preferably strawberry guarana, peppermint flavor or combination thereof.
  • PSD particle size distribution
  • the present formulation process for preparing the solid dosage forms of anhydrous mirtazapine led to unexpected results of possessing a more stable and reproducible dissolution profile.
  • the present formulation process of anhydrous mirtazapine unexpectedly demonstrated a more reproducible dissolution curve and a smaller standard deviation. This valuable improvement provides for more accurate dosing of mirtazapine.
  • the different formulation processes that can be employed for making the disclosed formulations are dry granulation, wet granulation, slugging, compaction and direct compression. But preferably, the tablets of the present invention are prepared by wet granulation technique.
  • the formulation process for the preparation of film coated tablets according to the present invention are carried out by sifting the ingredients, blending anhydrous mirtazapine with disintegrants, diluents and/or binders that are intended to be used; milling and then granulating the blend; drying the granules and sifting to get the desired size; mixing the dried granules with rest of the diluents, lubricants and compressing the blend to form tablets and coating the tablets using conventional coating techniques.
  • the formulation process for the preparation- of orally disintegrable tablet dosage form of mirtazapine according to the present invention are carried out by sifting the ingredients, blending anhydrous mirtazapine with disintegrants, diluents and/or binders that are intended to be used; milling the sifted materials; granulating the blend with the solvent; drying the granules and sifting to get the desired size; mixing the dried granules with rest of the diluents, lubricants, flavoring agents, sweetening agents, and compressing the blend to form tablets.
  • the process may also involve, the preparation of placebo granules as per the procedure explained in the above paragraph and adding the active ingredient during the lubrication stage.
  • Examples 2-4 represents orally disintegrating tablets of anhydrous mirtazapine.
  • the processing steps that are involved in making orally disintegrating tablets of anhydrous mirtazapine as disclosed in examples 2-4 are given below : - i) sifted mirtazapine, half the quantity of dispersing agent, binder, diluent through 425 ⁇ m mesh, ii) milled the sifted material of step (i) through multimill, iii) loaded the materials of step (ii) in a rapid mixer granulator and mixed for 15 minutes with impeller at slow speed, iv) added purified water over a period of 2-3 minutes with impeller at slow speed v) kneaded the wet mass for 1 minute with only impeller followed by both impeller and chopper at slow speed for 1 min, vi) dried the wet mass of step (v) at an inlet temperature of 60°C ⁇ 5°C in fluid bed drier, vii) sifted the dried granules

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques de mirtazapine ou de ses sels pharmaceutiquement acceptables. Plus spécifiquement, l'invention concerne des formes unitaires solides de mirtazapine anhydre ou de ses sels pharmaceutiquement acceptables à administration orale. L'invention concerne également un procédé de préparation de compositions pharmaceutiques de mirtazapine ou de ses sels pharmaceutiquement acceptables.
PCT/IB2004/003872 2003-11-25 2004-11-24 Compositions pharmaceutiques de mirtazapine WO2005051349A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04798978A EP1689371A2 (fr) 2003-11-25 2004-11-24 Compositions pharmaceutiques de mirtazapine
US10/580,391 US20070298107A1 (en) 2003-11-25 2004-11-24 Pharmaceutical Compositions of Mirtazapine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN964/CHE/2003 2003-11-25
IN964CH2003 2003-11-25
IN930/CHE/2004 2004-09-17
IN930CH2004 2004-09-17

Publications (2)

Publication Number Publication Date
WO2005051349A2 true WO2005051349A2 (fr) 2005-06-09
WO2005051349A3 WO2005051349A3 (fr) 2005-07-28

Family

ID=34635475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003872 WO2005051349A2 (fr) 2003-11-25 2004-11-24 Compositions pharmaceutiques de mirtazapine

Country Status (3)

Country Link
US (1) US20070298107A1 (fr)
EP (1) EP1689371A2 (fr)
WO (1) WO2005051349A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104095824A (zh) * 2013-04-09 2014-10-15 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001450B1 (fr) * 2006-03-31 2019-01-30 Rubicon Research Private Limited Mixture directement compressible pour la manufacture des comprimés se désagrégeant dans la cavité orale
WO2008079342A2 (fr) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Comprimés à désintégration par voie orale: composition utilisée et méthode de fabrication orale
CN103520169B (zh) * 2013-10-25 2015-07-15 山东鲁药制药有限公司 米氮平片及其制备方法
DK3261645T3 (da) 2015-02-27 2021-06-07 Dechra Ltd Stimulering af appetit, håndtering af vægttab og behandling af anoreksi hos hunde og katte
CN114917194A (zh) * 2022-04-29 2022-08-19 华裕(无锡)制药有限公司 一种米氮平片原料药及其制剂与制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
WO2001038329A1 (fr) * 1999-11-24 2001-05-31 Sumika Fine Chemicals Co., Ltd. Cristaux de mirtazapine anhydre et leur procede d'obtention
PL206073B1 (pl) * 2000-02-11 2010-06-30 Organon Nv Zastosowanie mirtazapiny do wytwarzania leku
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US6660730B2 (en) * 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
JP2003265943A (ja) * 2002-03-13 2003-09-24 Stec Inc 液体材料供給装置
EP1670441A4 (fr) * 2003-10-07 2012-05-02 Andrx Pharmaceuticals Llc Formulation a desintegration rapide
IS7724A (is) * 2005-03-02 2006-09-03 Actavis Group Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104095824A (zh) * 2013-04-09 2014-10-15 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法

Also Published As

Publication number Publication date
US20070298107A1 (en) 2007-12-27
EP1689371A2 (fr) 2006-08-16
WO2005051349A3 (fr) 2005-07-28

Similar Documents

Publication Publication Date Title
EP1027037B1 (fr) Preparation pharmaceutique comprenant du clodronate en tant que principe actif et de la cellulose microcristalline silicifiee en tant qu'excipient
EP1845954B1 (fr) Composition d'olanzapine ou de donepezil a desintegration orale
US7998505B2 (en) Dry granulation binders, products, and use thereof
US8591955B2 (en) Orally rapidly disintegrating tablet that contains two or more types of particles
JP2005533045A (ja) 経口崩壊錠およびその製造法
JPWO2009041651A1 (ja) 速崩壊性固形製剤
JPWO2009084678A1 (ja) 口腔内崩壊錠およびその製造方法
JPWO2003074085A1 (ja) 口腔内速崩壊性錠剤
JPWO2002032403A1 (ja) 口腔内速崩壊性医薬組成物およびその製造方法
JP2008285434A (ja) 口腔内速崩壊錠
JP2000119175A (ja) 口腔内速崩壊性固形製剤
JP2005507397A (ja) 速溶性の経口製剤
JP4438121B2 (ja) 口腔内速崩錠及びその製造方法
JP5466880B2 (ja) 口腔内崩壊錠
WO2006087629A2 (fr) Composition de medicament antipsychotique a delitement rapide
JP4711470B2 (ja) 崩壊補助剤、崩壊補助剤含有口腔内即（速）溶剤用組成物及び口腔内即（速）溶剤の製造方法
WO2005115346A9 (fr) Composition contenant de la risperidone
WO2009150665A1 (fr) Compositions pharmaceutiques à désintégration orale d’escitalopram et de sels de celui-ci
US6413541B1 (en) Disintegrating tablet in oral cavity and production thereof
BR112012010400B1 (pt) composição co-processada, processo para preparar uma composição útil como um excipiente farmacêutico, formulação de granulado ou comprimido, método, e, forma de dosagem sólida
US20070298107A1 (en) Pharmaceutical Compositions of Mirtazapine
WO2005077341A1 (fr) Compositions pharmaceutiques a desintegration orale d'ondansetron
JP2008127320A (ja) 口腔内速崩壊性固形製剤
US20070036852A1 (en) Rapidly dispersing/disintegrating compositions
JP2021167306A (ja) 崩壊性粒子の製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004798978

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004798978

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10580391

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10580391

Country of ref document: US